Pharma News

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs https://lnkd.in/dYF_rQmW Merus N.V. Biohaven Peter B. Silverman Brian Lestini #pharmanews #pharmaindustry #business

Epirium Bio : MF-300 is a first-in-class, orally administered, 15-PGDH enzyme inhibitor shown to restore muscle quality and strength in aged mice https://lnkd.in/dXhSMd2v #pharmaindustry #pharmanews #drugdevelopment Epirium Bio Scott Delp

Resalis Therapeutics Gains Strategic Equity Investment from Sanofi to accelerate the development of RES-010, a first-in-class antisense oligonucleotide targeting miR-22 (a non-coding RNA that plays a pivotal role in the molecular pathways underlying obesity) https://lnkd.in/dG9WH_Wj #pharmaindustry #obesity #drugdevelopment Resalis Therapeutics Sanofi Alessandro Toniolo

Immunome : Preclinical evaluation of IM-1021, a ROR1-targeted antibody-drug conjugate with a novel topoisomerase I linker payload https://lnkd.in/df8YZZ-P #pharmaindustry #antibodies #ADC Immunome, Inc. Max Rosett Clay Siegall, PhD

Genexine Announces Merger with EPD Biotherapeutics, a company developing an innovative targeted protein degradation (TPD) bioPROTAC platform technology, to Strengthen Drug Development Pipeline https://lnkd.in/dSPPstdc #pharmaindustry #pharmanews #therapeutics Genexine, Inc. EPD Biotherapeutics Inc. Sung June Hong Jaehyun Choi

Agomab Therapeutics : FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis. AGMB-447 is an inhaled lung-restricted ALK5-inhibitor currently in a Phase 1 clinical trial. https://lnkd.in/dxBE3_56 #pharmaindustry #pharmanews #FDA Agomab Philippe Wiesel Tim Knotnerus Stephanie May Gretchen Schweitzer

Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo? (cemiplimab)?https://lnkd.in/eEVrDYSm #pharmaindustry #antibodies #immunotherapies Regeneron American Society of Clinical Oncology (ASCO) Neil Segal Israel Lowy Taylor Ramsey Skott Vesna Tosic, Ph.D.

Sinaptica Therapeutics?: a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s (AD) and other neurodegenerative diseases. The company utilizes a patented, non-invasive approach to treating Alzheimer’s via precision neurostimulation of a key brain network involved in memory, the Default Mode Network https://lnkd.in/d7dkGSDu #alzheimers #neurostimulation #medtech Sinaptica Therapeutics Gates Ventures Melinda French Gates Ken Mariash Steven Krein StartUp Health

Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma https://lnkd.in/dQEUnN_J #CARTcells #celltherapy #FDA Bristol Myers Squibb FDA Bryan Campbell Lia Palomba Meghan Gutierrez

WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval for WGc-043, the world's first approval of an EB virus-related mRNA therapeutic cancer vaccine https://lnkd.in/dVAEaAB4 #cancervaccine #mRNA #pharmaindustry WestGene